ly3437943 retatrutide triple agonist glp-1 gip glucagon Guide 2023: Weight Loss, Benefits, Results, Dosage Retatrutide: A metabolic upgrade for

GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials

While tirzepatide made history as the first dual GIP/GLP-1 receptor agonist to receive FDA approval, retatrutide pushes the pharmacological envelope further with triple receptor agonism that adds glucagon receptor activation

Low blood sugar may occur if these weight management medications are taken in addition to glucose-lowering drugs that can cause hypoglycemia (eg, insulin or a sulfonylurea)

doi: 10.7759/CUREUS.51352 69 ZhaoCLiangJYangYYuMQuX

It works by reducing appetite and helping patients achieve significant weight loss

8 Challenges in clinical application Considering the enumerated benefits of GLP-1RA compared to other glucose-lowering drugs including the reduction in HbA1c and weight reduction benefits alongside decreased risk for hypoglycaemia (122) it is not cost effective if used in combination with another incretin (107)